These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20177421)

  • 1. In silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolizes a p38 kinase inhibitor.
    Zhang X; Liu HH; Weller P; Zheng M; Tao W; Wang J; Liao G; Monshouwer M; Peltz G
    Pharmacogenomics J; 2011 Feb; 11(1):15-24. PubMed ID: 20177421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-type p38 mitogen-activated protein kinase inhibitor.
    Kammerer B; Scheible H; Albrecht W; Gleiter CH; Laufer S
    Drug Metab Dispos; 2007 Jun; 35(6):875-83. PubMed ID: 17344341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
    Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
    J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Species differences in enantioselective 2-oxidations of RS-8359, a selective and reversible MAO-A inhibitor, and cinchona alkaloids by aldehyde oxidase.
    Itoh K; Yamamura M; Takasaki W; Sasaki T; Masubuchi A; Tanaka Y
    Biopharm Drug Dispos; 2006 Apr; 27(3):133-9. PubMed ID: 16400710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Aldehyde Oxidase 1-Mediated Carbazeran Oxidation in Chimeric TK-NOG Mice Transplanted with Human Hepatocytes.
    Uehara S; Yoneda N; Higuchi Y; Yamazaki H; Suemizu H
    Drug Metab Dispos; 2020 Jul; 48(7):580-586. PubMed ID: 32357972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans.
    Akabane T; Tanaka K; Irie M; Terashita S; Teramura T
    Xenobiotica; 2011 May; 41(5):372-84. PubMed ID: 21385103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Cloning and Characterization of Marmoset Aldehyde Oxidase.
    Uehara S; Uno Y; Okamoto E; Inoue T; Sasaki E; Yamazaki H
    Drug Metab Dispos; 2017 Aug; 45(8):883-886. PubMed ID: 28487309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences.
    Dalvie D; Zhang C; Chen W; Smolarek T; Obach RS; Loi CM
    Drug Metab Dispos; 2010 Apr; 38(4):641-54. PubMed ID: 20040581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphism of aldehyde oxidase in Donryu rats.
    Itoh K; Masubuchi A; Sasaki T; Adachi M; Watanabe N; Nagata K; Yamazoe Y; Hiratsuka M; Mizugaki M; Tanaka Y
    Drug Metab Dispos; 2007 May; 35(5):734-9. PubMed ID: 17293383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldehyde oxidase importance in vivo in xenobiotic metabolism: imidacloprid nitroreduction in mice.
    Swenson TL; Casida JE
    Toxicol Sci; 2013 May; 133(1):22-8. PubMed ID: 23462233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
    Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
    Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldehyde oxidase 1 (AOX1) in human liver cytosols: quantitative characterization of AOX1 expression level and activity relationship.
    Fu C; Di L; Han X; Soderstrom C; Snyder M; Troutman MD; Obach RS; Zhang H
    Drug Metab Dispos; 2013 Oct; 41(10):1797-804. PubMed ID: 23857892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase.
    Chopra P; Kulkarni O; Gupta S; Bajpai M; Kanoje V; Banerjee M; Bansal V; Visaga S; Chatterjee M; Chaira T; Shirumalla RK; Verma AK; Dastidar SG; Sharma G; Ray A
    Int Immunopharmacol; 2010 Apr; 10(4):467-73. PubMed ID: 20093202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interspecies differences in the metabolism of methotrexate: An insight into the active site differences between human and rabbit aldehyde oxidase.
    Choughule KV; Joswig-Jones CA; Jones JP
    Biochem Pharmacol; 2015 Aug; 96(3):288-95. PubMed ID: 26032640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction.
    Mbalaviele G; Anderson G; Jones A; De Ciechi P; Settle S; Mnich S; Thiede M; Abu-Amer Y; Portanova J; Monahan J
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1044-53. PubMed ID: 16501068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase.
    Acheampong AA; Chien DS; Lam S; Vekich S; Breau A; Usansky J; Harcourt D; Munk SA; Nguyen H; Garst M; Tang-Liu D
    Xenobiotica; 1996 Oct; 26(10):1035-55. PubMed ID: 8905918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of aldehyde oxidase in drug metabolism.
    Garattini E; Terao M
    Expert Opin Drug Metab Toxicol; 2012 Apr; 8(4):487-503. PubMed ID: 22335465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
    Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR
    J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase.
    Zientek M; Jiang Y; Youdim K; Obach RS
    Drug Metab Dispos; 2010 Aug; 38(8):1322-7. PubMed ID: 20444863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.